# EDAP TMS S.A. share price today (EDAP TMS S.A., FOCL)

> EDAP TMS S.A.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. FOCL · Healthcare · Medical Distribution · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/focl

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $4.11 (+92.1% in a year)
- Revenue (Jun 2026): $13.2 M
- Profit (Jun 2026), incl. one-off: −$14.5 M (one-off item, see below)
- Operating margin: −60.8%
- ROE: −151%, FY25
- ROIC: −90.4%, against a 6.4% cost of capital: −96.8 points

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the EDAP TMS S.A. share price today? EDAP TMS S.A.'s share price was $4.11 at the close on 3 November 2026. That is 6.8% below its average price over the last 200 trading days. In the last 52 weeks it traded between $2 and $6, and at that close it sat 50% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 12 weeks running. Over the last 1 year the share price moved +170% while the S&P 500 moved +21%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 14 August 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does EDAP TMS S.A. pay? EDAP TMS S.A. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is EDAP TMS S.A. on? EDAP TMS S.A. is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is EDAP TMS S.A. profitable? EDAP TMS S.A. posted a net loss of $14.5 M in the Jun 2026 quarter. That quarter includes a one-off gain bigger than its revenue, so the comparison with last year does not reflect normal business. The full FY25 year was a loss of $29.2 M. That loss is 109.7% of the quarter's revenue. The same quarter a year earlier lost $6.6 M. 8 of the last 8 reported quarters were loss-making. Read this profit with care: at −$14.5 M it is bigger than the quarter's whole revenue of $13.2 M. No business earns more than it takes in from sales, so this is a one-off item (for example a debt settlement, a tax write-back or an asset sale), not money the business earned. The underlying business is running at a −60.8% operating margin. The jump on last year, and any P/E built on this profit, come from the one-off, not from a real turn in earnings. ## How much revenue does EDAP TMS S.A. make, and is it growing? EDAP TMS S.A. reported $13.2 M of revenue in the Jun 2026 quarter. Over 4 years it has grown 8.9% a year on average. The last full year, FY25, came in at $70.5 M. The quarterly figures for FY25 do not add up to the full-year total on file, so those quarters are left out of the charts and sums. FY25 revenue was $70.5 M, +1.6% on the year before. ## How much of every $100 of sales does EDAP TMS S.A. keep? EDAP TMS S.A.'s operating margin was −60.8% in the Jun 2026 quarter. Across 5 years it has been between −35.0% and −3.7%. The latest quarter is below every full year in that period. Why the margin moved: operating margin changed −21.9 percentage points on the year while gross margin changed +18.1 points. So the drop came mostly from the gross margin, which means input costs and prices charged. ## Is EDAP TMS S.A.'s profit turning into cash? EDAP TMS S.A.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used $16.4 M of cash, against −$29.2 M of profit. After $4.9 M of spending on assets, free cash was −$21.3 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does EDAP TMS S.A.'s cash go? EDAP TMS S.A. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $13.3 M on assets over the last 3 years. Averaged over those years that is 6.3% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $13.3 M over the last 3 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is EDAP TMS S.A.'s P/E ratio, and how does it compare with its own history? EDAP TMS S.A. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values EDAP TMS S.A. at 2.7× its FY25 revenue of $70.5 M. The P/E comes back here once profit turns positive. ## Is the EDAP TMS S.A. business getting better or worse? EDAP TMS S.A.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 6 quarters of 0 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading. The return-on-capital line is not shown: net worth is negative, so a return on capital means nothing. The balance sheet is in distress, and this reading uses the growth lines alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does EDAP TMS S.A. earn on its capital? EDAP TMS S.A. earned a ROE of −151% in FY25. Its return on capital used (ROIC) is 96.8 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a −41.5% net margin and 0.89× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −41.5% net margin × 0.89× asset turnover × 4.07× leverage (assets divided by equity) ≈ −150.3% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: −90.4% − 6.4% = −96.8 percentage points. The 6.4% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. The −90.4% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at −93.7%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does EDAP TMS S.A. have too much debt? EDAP TMS S.A.'s net worth is negative: it owes more than it owns, so a debt-to-equity ratio means nothing here. Year by year, that ratio went from 0.20 in FY21 to 1.43 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the EDAP TMS S.A. shareholding pattern? 1.0% of EDAP TMS S.A.'s tradable shares are in short positions, which are bets that the price will fall, so very few traders are betting against this stock. At normal trading volumes, closing those positions would take about 4.6 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is EDAP TMS S.A. from balance-sheet trouble? For EDAP TMS S.A., the Z-score is −1.76. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of −1.76 is inside the danger zone, so the balance sheet is a real risk. ## How does EDAP TMS S.A. rank in its industry? 28.4 out of 100, rank 6 of 8 in Medical Distribution, with 67% of the evidence available. EDAP TMS S.A. scores 28.4 out of 100 against the 8 companies it is compared with in Medical Distribution, ranking 6. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 14.2 + 3 + 8.5 + 2.7 = 28.4. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is EDAP TMS S.A. compared with? EDAP TMS S.A. ranks 6 of 8 Medical Distribution companies on the 4-Factor Sector Score, with 28.4 out of 100. 1. [McKesson Corporation](https://www.sectoralpha.in/us/stocks/mck) MCK · leader · Most evidence points up · 85% evidence 79.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.7/35 · Revenue 8.8% · Profit 58.1% · Operating margin change 0 points · 95% evidence Capital efficiency 18.2/25 · ROCE 36.7% · Operating margin 1.3% · 76% evidence Valuation 16.0/20 · P/E 19.3× · PEG 0.39 · 65% evidence Relative strength 20.0/20 · Lead over its industry 12% · Lead over S&P 500 10.5% · 1 year 17.3% · 100% evidence · 12 of 12 weeks ahead Exact sum: 25.7 + 18.2 + 16 + 20 = 79.9 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Cencora, Inc.](https://www.sectoralpha.in/us/stocks/cor) COR · breaking out · Evidence leans up · 85% evidence 63.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.7/35 · Revenue 5.1% · Profit 38.4% · Operating margin change 0.2 points · 95% evidence Capital efficiency 14.9/25 · ROCE 18.3% · Operating margin 1.4% · 76% evidence Valuation 15.5/20 · P/E 21× · PEG 0.54 · 65% evidence Relative strength 13.5/20 · Lead over its industry 1.3% · Lead over S&P 500 -0.1% · 1 year -5.6% · 100% evidence · 8 of 12 weeks ahead Exact sum: 19.7 + 14.9 + 15.5 + 13.5 = 63.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Cardinal Health, Inc.](https://www.sectoralpha.in/us/stocks/cah) CAH · turning · Evidence leans up · 85% evidence 58.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.9/35 · Revenue 14.2% · Profit 9.8% · Operating margin change 0.2 points · 95% evidence Capital efficiency 15.9/25 · ROCE 24.5% · Operating margin 1.3% · 76% evidence Valuation 5.0/20 · P/E 32.5× · PEG 2.72 · 65% evidence Relative strength 16.6/20 · Lead over its industry 11.2% · Lead over S&P 500 9.8% · 1 year 24.2% · 100% evidence · 7 of 12 weeks ahead Exact sum: 20.9 + 15.9 + 5 + 16.6 = 58.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Henry Schein, Inc.](https://www.sectoralpha.in/us/stocks/hsic) HSIC · quiet · Evidence leans down · 85% evidence 41.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.6/35 · Revenue 6.5% · Profit 6% · Operating margin change 0.4 points · 95% evidence Capital efficiency 12.6/25 · ROCE 9.9% · Operating margin 5.8% · 76% evidence Valuation 7.3/20 · P/E 24× · PEG 2.33 · 65% evidence Relative strength 7.4/20 · Lead over its industry -0.6% · Lead over S&P 500 -1.8% · 1 year 14.7% · 100% evidence · 4 of 12 weeks ahead Exact sum: 14.6 + 12.6 + 7.3 + 7.4 = 41.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Akso Health Group](https://www.sectoralpha.in/us/stocks/ahg) AHG · basing · Too little evidence to rank firmly · 51% evidence 35.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.2/35 · Revenue n/a · Profit n/a · Operating margin change 5.6 points · 26% evidence Capital efficiency 4.8/25 · ROCE -2.2% · Operating margin -37.5% · 76% evidence Valuation 9.5/20 · P/E 25.6× · PEG n/a · 15% evidence Relative strength 3.7/20 · Lead over its industry -20.9% · Lead over S&P 500 -23.3% · 1 year -22.9% · 100% evidence · 0 of 12 weeks ahead Exact sum: 17.2 + 4.8 + 9.5 + 3.7 = 35.2 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 6. EDAP TMS S.A. this page FOCL · quiet · Most evidence points down · 67% evidence 28.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.2/35 · Revenue 7.1% · Profit n/a · Operating margin change 8.8 points · 71% evidence Capital efficiency 3.0/25 · ROCE -71.4% · Operating margin -60.8% · 76% evidence Valuation 8.5/20 · P/E 71.3× · PEG n/a · 15% evidence Relative strength 2.7/20 · Lead over its industry -2.6% · Lead over S&P 500 -4.3% · 1 year 103.5% · 100% evidence · 0 of 12 weeks ahead Exact sum: 14.2 + 3 + 8.5 + 2.7 = 28.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. Empro Group Inc. EMPG · Too little evidence to rank firmly · 16% evidence 56.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.7/43.75 · Revenue n/a · Profit n/a · Operating margin change 65.6 points · 5% evidence Capital efficiency 21.6/31.25 · ROCE 39.6% · Operating margin 36.1% · 57% evidence Valuation 12.5/25 · P/E n/a · PEG n/a · 0% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 22.7 + 21.6 + 12.5 = 56.8 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 8. Accendra Health, Inc. ACH · Too little evidence to rank firmly · 38% evidence 36.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.7/43.75 · Revenue n/a · Profit n/a · Operating margin change -8.7 points · 45% evidence Capital efficiency 8.6/31.25 · ROCE 4.3% · Operating margin -1.5% · 76% evidence Valuation 14.4/25 · P/E -35.7× · PEG n/a · 15% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 13.7 + 8.6 + 14.4 = 36.7 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Jun 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Medical Distribution](https://www.sectoralpha.in/us/sectors/medical-distribution), all 8 compared on one page. ## Which companies are close to EDAP TMS S.A. in size? EDAP TMS S.A. is the 6th largest of 6 Medical Distribution companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: McKesson Corporation, Cencora, Inc., Cardinal Health, Inc., Henry Schein, Inc. and Akso Health Group. It is the smallest. ### Medical Distribution companies close in size

1. [McKesson Corporation](https://www.sectoralpha.in/us/stocks/mck) $116.5 billion
2. [Cencora, Inc.](https://www.sectoralpha.in/us/stocks/cor) $65 billion
3. [Cardinal Health, Inc.](https://www.sectoralpha.in/us/stocks/cah) $58.6 billion
4. [Henry Schein, Inc.](https://www.sectoralpha.in/us/stocks/hsic) $9.2 billion
5. [Akso Health Group](https://www.sectoralpha.in/us/stocks/ahg) $1 billion
6. EDAP TMS S.A. $189 million

[All 6 Medical Distribution companies, largest first](https://www.sectoralpha.in/us/sectors/medical-distribution#all-companies)

## What else do people ask about EDAP TMS S.A.? ### What were EDAP TMS S.A.'s latest quarterly results? EDAP TMS S.A. reported revenue of $13.2 M and a net loss of $14.5 M for the Jun 2026 quarter. Earnings per share were −$0.39. The operating margin was −60.8% (as of 3 November 2026). ### What is EDAP TMS S.A.'s market cap? EDAP TMS S.A.'s market capitalisation is $189 M at a stock price of $4.11. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is EDAP TMS S.A. performing? EDAP TMS S.A.'s latest readings are below. Over the past 13 weeks it has done worse than the S&P 500, for 12 weeks running. This describes what the data did, not a rating (as of 3 November 2026). ### Will EDAP TMS S.A.'s stock price go up? This page does not forecast EDAP TMS S.A.'s stock price. What it shows instead: the stock price is $4.11. Nobody can reliably say which way a price will move, and this site does not try (as of 3 November 2026). ### Does EDAP TMS S.A. have too much debt? Yes, EDAP TMS S.A. has a lot of debt: its debt is 2.75× its equity. A year-by-year history of its borrowings is not in our data, so this uses the latest reading. Keep that borrowing in mind when reading the returns on this page (as of 3 November 2026). ### Where is EDAP TMS S.A. in its business cycle? EDAP TMS S.A.'s FY25 operating margin was −35.0%, against a 5-year range of −35.0% to −3.7%: the low end of its own range, which is often where recoveries start. The latest quarter was −60.8%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the EDAP TMS S.A. story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is EDAP TMS S.A. a stock worth studying right now? What the numbers show: EDAP TMS S.A.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.